Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $88.77 Consensus PT from Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have been given an average recommendation of “Moderate Buy” by the thirteen research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $88.77.

Several research firms recently weighed in on RARE. William Blair began coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an “outperform” rating and a $65.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Canaccord Genuity Group raised their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. Piper Sandler decreased their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a research report on Monday, March 17th. Finally, Morgan Stanley raised their target price on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an “overweight” rating in a research report on Friday, May 9th.

Institutional Trading of Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 323 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 493 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in Ultragenyx Pharmaceutical in the 4th quarter worth approximately $35,000. Human Investing LLC purchased a new position in Ultragenyx Pharmaceutical in the 4th quarter worth approximately $42,000. Finally, ANTIPODES PARTNERS Ltd purchased a new position in Ultragenyx Pharmaceutical in the 1st quarter worth approximately $57,000. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Stock Up 4.7%

Shares of NASDAQ RARE opened at $39.29 on Friday. Ultragenyx Pharmaceutical has a twelve month low of $29.59 and a twelve month high of $60.37. The stock’s 50 day moving average price is $35.91 and its 200-day moving average price is $40.15. The company has a market capitalization of $3.71 billion, a PE ratio of -6.20 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business had revenue of $139.29 million during the quarter, compared to analysts’ expectations of $145.98 million. During the same quarter in the previous year, the firm earned ($2.03) EPS. Ultragenyx Pharmaceutical’s quarterly revenue was up 28.0% on a year-over-year basis. As a group, research analysts expect that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.